• Mutation; HGNC; 11998; TP53; Simple; p.Ala161Thr (c.481G>A); ClinVar=VCV000161518; Zygosity=Homozygous (PubMed=9249875).
  

CLPUB00455
Koskela K., Pelliniemi T.-T., Remes K., Savino R., Ciliberto G., Pulkki K.
Establishment of three new myeloma cell lines from bone marrow plasma cells: response to interleukin-6 and interleukin-6-antagonist.
(In) Vth international workshop on multiple myeloma; pp.3.83-3.83; La Baule (1995)

PubMed=9249875; DOI=10.3109/00365519709099401
Ollikainen H., Syrjanen S.M., Koskela K., Pelliniemi T.-T., Pulkki K.
p53 gene mutations are rare in patients but common in patient-originating cell lines in multiple myeloma.
Scand. J. Clin. Lab. Invest. 57:281-289(1997)

PubMed=10936422; DOI=10.1016/S0145-2126(99)00195-2
Drexler H.G., Matsuo Y.
Malignant hematopoietic cell lines: in vitro models for the study of multiple myeloma and plasma cell leukemia.
Leuk. Res. 24:681-703(2000)

PubMed=11818668; DOI=10.1159/000046625
Koskela K., Pelliniemi T.-T., Pelliniemi L.J., Remes K., Soderstrom K.-O., Punnonen K., Kumar R., Ollikainen H., Pulkki K.
Autocrine production and synergistic growth-promoting activity of interleukin-6 and oncostatin M in a new human myeloma cell line TU-1.
Acta Haematol. 107:23-28(2002)